Liquidia (NASDAQ:LQDA) Stock: Insider Michael Kaseta Sells 18,938 Shares

Posted by Brian Himes on Oct 15th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CFO Michael Kaseta sold 18,938 shares of Liquidia stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $539,354.24. Following the completion of the sale, the chief financial officer directly owned 340,148 shares of the company’s stock, valued at approximately $9,687,415.04. The trade was a 5.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 26.6%

Shares of LQDA stock opened at $33.94 on Thursday. The stock’s 50 day simple moving average is $62.30 and its 200 day simple moving average is $61.74. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The company has a market capitalization of $3.04 billion, a price-to-earnings ratio of 24.77 and a beta of 0.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the firm earned ($0.49) EPS. The firm’s revenue was up 1842.1% on a year-over-year basis. As a group, research analysts predict that Liquidia Corporation will post 2.05 EPS for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

Analyst Ratings Changes

A number of research analysts have recently commented on LQDA shares. Citigroup reiterated a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. HC Wainwright reduced their price objective on Liquidia from $130.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, October 2nd. Zacks Research downgraded shares of Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Raymond James Financial reaffirmed an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. Finally, Needham & Company LLC dropped their target price on shares of Liquidia from $72.00 to $58.00 and set a “buy” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $77.31.

Get Our Latest Analysis on LQDA

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LQDA. Quantinno Capital Management LP lifted its stake in shares of Liquidia by 3.6% in the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after buying an additional 589 shares during the period. Arizona State Retirement System grew its position in Liquidia by 5.4% during the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after buying an additional 900 shares in the last quarter. Swiss National Bank increased its stake in Liquidia by 1.3% during the first quarter. Swiss National Bank now owns 120,400 shares of the company’s stock valued at $4,544,000 after acquiring an additional 1,600 shares during the period. Valmark Advisers Inc. increased its stake in Liquidia by 10.2% during the first quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock valued at $775,000 after acquiring an additional 1,905 shares during the period. Finally, Globeflex Capital L P bought a new position in Liquidia during the second quarter valued at about $175,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).